A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
Th1186 details |
| Primary information | |
|---|---|
| ID | 1768 |
| ThPP ID | Th1186 |
| Therapeutic Peptide/Protein Name | Human rabies virus immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIa |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | NA |
| Indication/Disease | It is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with HDCV Rabies Vaccine in a pre-exposure or postexposure treatment series should receive only vaccine. |
| Pharmacodynamics | NA |
| Mechanism of Action | It provides passive protection by neutralizing the rabies virus when given to individuals exposed to rabies virus. When a rabies immune globulin dose of 20 IU/kg was given simultaneously with the first dose of rabies vaccine, levels of passive anti-rabies antibody were detected 24 hours after injection in all individuals. There was minimal or no interference with the immune response to the initial and subsequent doses of rabies vaccine, including booster doses. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Live virus vaccines, such as measles vaccine, should not be given for four months following Human rabies virus immune globulin administration because antibodies in the immune globulin preparation may interfere with the immune response to the vaccine. |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Hyperab Rabies Immune Globulin Human |
| Company | Cutter Med & Biol, Division Of Miles Canada Ltd. |
| Brand Discription | |
| Prescribed for | |
| Chemical Name | |
| Formulation | 16.50% |
| Physcial Appearance | Liquid |
| Route of Administration | intramuscular |
| Recommended Dosage | The recommended dose for HyperRAB S/D is 20 IU/kg (0.133 mL/kg) of body weight given preferably at the time of the first vaccine dose |
| Contraindication | Hypersensitivity |
| Side Effects | Fever, pain, soreness, tenderness, or stiffness at the injection site, Skin rash |
| Useful Link | https://www.drugs.com/ |
| PubMed ID | 10675760 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1769 |
| ThPP ID | Th1186 |
| Therapeutic Peptide/Protein Name | Human rabies virus immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIa |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | NA |
| Indication/Disease | It is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with HDCV Rabies Vaccine in a pre-exposure or postexposure treatment series should receive only vaccine. |
| Pharmacodynamics | NA |
| Mechanism of Action | It provides passive protection by neutralizing the rabies virus when given to individuals exposed to rabies virus. When a rabies immune globulin dose of 20 IU/kg was given simultaneously with the first dose of rabies vaccine, levels of passive anti-rabies antibody were detected 24 hours after injection in all individuals. There was minimal or no interference with the immune response to the initial and subsequent doses of rabies vaccine, including booster doses. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Live virus vaccines, such as measles vaccine, should not be given for four months following Human rabies virus immune globulin administration because antibodies in the immune globulin preparation may interfere with the immune response to the vaccine. |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Hyperrab S/d |
| Company | Grifols Therapeutics Inc |
| Brand Discription | Rabies immune globulin is used together with rabies vaccine to prevent infection caused by the rabies virus. Rabies immune globulin works by giving your body the antibodies it needs to protect it against the rabies virus. |
| Prescribed for | Rabies immune globulin is used together with rabies vaccine to prevent infection caused by the rabies virus. |
| Chemical Name | NA |
| Formulation | 150 unit |
| Physcial Appearance | Solution |
| Route of Administration | intramuscular |
| Recommended Dosage | The recommended dose for HyperRAB S/D is 20 IU/kg (0.133 mL/kg) of body weight given preferably at the time of the first vaccine dose |
| Contraindication | Hypersensitivity |
| Side Effects | Fever, pain, soreness, tenderness, or stiffness at the injection site, Skin rash |
| Useful Link | https://www.drugs.com/cons/hyperrab-s-d.html |
| PubMed ID | 10675760 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1770 |
| ThPP ID | Th1186 |
| Therapeutic Peptide/Protein Name | Human rabies virus immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIa |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | NA |
| Indication/Disease | It is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with HDCV Rabies Vaccine in a pre-exposure or postexposure treatment series should receive only vaccine. |
| Pharmacodynamics | NA |
| Mechanism of Action | It provides passive protection by neutralizing the rabies virus when given to individuals exposed to rabies virus. When a rabies immune globulin dose of 20 IU/kg was given simultaneously with the first dose of rabies vaccine, levels of passive anti-rabies antibody were detected 24 hours after injection in all individuals. There was minimal or no interference with the immune response to the initial and subsequent doses of rabies vaccine, including booster doses. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Live virus vaccines, such as measles vaccine, should not be given for four months following Human rabies virus immune globulin administration because antibodies in the immune globulin preparation may interfere with the immune response to the vaccine. |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Imogam Rabies Inj 150unit/ml |
| Company | Pasteur mÉrieux Serums Et Vaccins, s.a. |
| Brand Discription | Imogam Rabies Pasteurised is a medicine containing the active ingredient(s) rabies virus immunoglobulin. |
| Prescribed for | Rabies immune globulin is used together with rabies vaccine to prevent infection caused by the rabies virus. |
| Chemical Name | |
| Formulation | 151 unit |
| Physcial Appearance | Clear, pale yellow to light brown liquid |
| Route of Administration | intramuscular |
| Recommended Dosage | The recommended dose of IMOGAM® Rabies is 20 IU/kg (0.133 mL/kg) of body weight at the time of administration of the first dose of rabies vaccine. |
| Contraindication | IMOGAM® Rabies should not be administered as repeat doses once rabies vaccination has been in itiated. Repeating the dose may interfere with maximum active immunity expected to develop from the rabies vaccine. |
| Side Effects | Hypotension, Tachycardia, Nausea, Vomiting, Local reaction, Fever, chills, Allergic type reaction, Anaphylactic shock, General prurit, Rash |
| Useful Link | http://rxisk.org/drug/2227/Rabies-Immune-Globulin-(Human)/92364/Imogam-Rabies-Pasteurized/ |
| PubMed ID | 10675760 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1771 |
| ThPP ID | Th1186 |
| Therapeutic Peptide/Protein Name | Human rabies virus immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIa |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | NA |
| Indication/Disease | It is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with HDCV Rabies Vaccine in a pre-exposure or postexposure treatment series should receive only vaccine. |
| Pharmacodynamics | NA |
| Mechanism of Action | It provides passive protection by neutralizing the rabies virus when given to individuals exposed to rabies virus. When a rabies immune globulin dose of 20 IU/kg was given simultaneously with the first dose of rabies vaccine, levels of passive anti-rabies antibody were detected 24 hours after injection in all individuals. There was minimal or no interference with the immune response to the initial and subsequent doses of rabies vaccine, including booster doses. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Live virus vaccines, such as measles vaccine, should not be given for four months following Human rabies virus immune globulin administration because antibodies in the immune globulin preparation may interfere with the immune response to the vaccine. |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Imogam Rabies Pasteurized |
| Company | Sanofi Pasteur Limited |
| Brand Discription | IMOGAM® Rabies Pasteurized [Rabies Immune Globulin (RIG), Pasteurized (Human)] is a sterile solution of antirabies immune globulins (10-16% protein) for intramuscular administration. |
| Prescribed for | It is indicated for post-exposure prophylaxis in persons suspected of exposure to rabies, who have not previously received a complete immunization regimen with a cell culture produced rabies vaccine. |
| Chemical Name | |
| Formulation | Human proteins (100-160 mg) containing IgG-class human rabies immune globulins with a minimum titre of 150 IU/mL. Supplied in 2 mL vial s (300 IU) and 10 mL vials (1,500 IU). |
| Physcial Appearance | Solution |
| Route of Administration | intramuscular |
| Recommended Dosage | The recommended dose of IMOGAM® Rabies Pasteurized is 20 IU/kg (0.133 mL/kg) of body weight at the time of administration of the first dose of rabies vaccine. |
| Contraindication | IMOGAM® Rabies Pasteurized should not be administered as repeat doses once rabies vaccination has been in itiated. Repeating the dose may interfere with maximum active immunity expected to develop from the rabies vaccine. |
| Side Effects | Hypotension, Tachycardia, Nausea, Vomiting, Local reaction, Fever, chills, Allergic type reaction, Anaphylactic shock, General prurit, Rash |
| Useful Link | https://www.vaccineshoppecanada.com/document.cfm?file=imogam_rabies_e.pdf |
| PubMed ID | 10675760 |
| 3-D Structure | N.A. |